Literature DB >> 26895682

Islet Cell Tumors of the Pancreas.

Sunil Amin1, Michelle Kang Kim2.   

Abstract

Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Islet cell tumor; Pancreas; Pancreas cancer; Pancreatic neuroendocrine tumors (PNET); Targeted molecular therapy

Mesh:

Substances:

Year:  2016        PMID: 26895682     DOI: 10.1016/j.gtc.2015.10.007

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  8 in total

1.  Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.

Authors:  Joo Young Kim; Sang Hwa Lee; Soyeon An; Sung Joo Kim; You-Na Sung; Ki-Byung Song; Dae Wook Hwang; Song Cheol Kim; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2018-04-18       Impact factor: 4.064

2.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

Review 3.  Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Authors:  Sergio Pedraza-Arévalo; Manuel D Gahete; Emilia Alors-Pérez; Raúl M Luque; Justo P Castaño
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

4.  Risk of malignancy and prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors.

Authors:  Xi Liu; Wenjie Chin; Chenggeng Pan; Weichen Zhang; Jun Yu; Shusen Zheng; Yuanxing Liu
Journal:  Gland Surg       Date:  2021-01

5.  Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients.

Authors:  Sung Joo Kim; Soyeon An; Jae Hoon Lee; Joo Young Kim; Ki-Byung Song; Dae Wook Hwang; Song Cheol Kim; Eunsil Yu; Seung-Mo Hong
Journal:  J Pathol Transl Med       Date:  2017-06-08

6.  Trends in Incidence and Survival of Patients with Pancreatic Neuroendocrine Neoplasm, 1987-2016.

Authors:  Jingxuan Wang; Jianhua Liu; Chao He; Tiantian Sun; Yan Yan; Gang Che; Xuemin Li; Huanhuan Sun; Haiqing Ma
Journal:  J Oncol       Date:  2021-12-22       Impact factor: 4.375

Review 7.  Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies.

Authors:  Marina Ayres Pereira; Iok In Christine Chio
Journal:  Genes (Basel)       Date:  2019-12-19       Impact factor: 4.096

8.  Diagnosis value preoperative localization of insulinoma by diffusion-weighted imaging: A pilot study.

Authors:  Li-Jun Chen; Yue-Dong Han; Ming Zhang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.